Table 1.
Study patient clinical characteristics
| Controls (n=53) | Psoriasis (n=100) | p-value | |
|---|---|---|---|
| Mean ± sd or N (%) | Mean ± sd or N (%) | ||
| Demographics | |||
| *Age (years) | 45.1±18.0 | 46.3±16.2 | 0.596 |
| *Male gender | 26 (49.1%) | 52 (52.0%) | 0.729 |
| Other Race (vs. white race) | 8 (15.1%) | 13 (13.0%) | 0.720 |
| Conventional cardiovascular risk factors | |||
| *BMI (kg/m2) | 29.1±6.4 | 30.1±7.4 | 0.532 |
| WHR | 0.90±0.07 | 0.93±0.08 | 0.022 |
| WC (cm) | 39.0±5.8 | 40.1±6.5 | 0.350 |
| Fasting blood glucose (mg/dL) | 91.8±21.2 | 95.2±29.3 | 0.836 |
| Systolic BP (mmHg) | 119.4±15.5 | 128.1±16.8 | 0.002 |
| Diastolic BP (mmHg) | 73.6±8.5 | 79.5±9.7 | <0.001 |
| LDL (mg/dL) | 110.3±35.1 | 119.5±36.2 | 0.164 |
| HDL (mg/dL) | 55.3±13.3 | 51.1±14.7 | 0.046 |
| Total cholesterol (mg/dL) | 189.1±44.6 | 196.3±45.4 | 0.397 |
| Triglyceride (mg/dL) | 121.5±109.0 | 125.4±82.8 | 0.368 |
| Creatinine (mg/dL) | 1.0±0.3 | 1.0±0.2 | 0.857 |
| BUN (mg/dL) | 14.8±4.9 | 13.8±4.7 | 0.234 |
| Current cigarette smoker | 12 (22.6%) | 38 (38.0%) | 0.034 |
| Heart attack, stents, angioplasty, bypass surgery (personal) | 2 (3.8%) | 3 (3.0%) | 1.000 |
| Stroke (personal) | 0 (0%) | 0 (0%) | 1.000 |
| Premature heart attack (family) | 20 (37.7%) | 38 (38.0%) | 0.974 |
| Stroke (family) | 14 (26.4%) | 44 (44.0%) | 0.033 |
| Current medication use | |||
| Aspirin | 6 (11.3%) | 13 (13.0%) | 0.760 |
| Statins | 9 (17.0%) | 16 (16.0%) | 0.876 |
| ACE inhibitors | 4 (7.6%) | 14 (14.0%) | 0.239 |
*
Age, gender and BMI were group matched.
ACE inhibitors: angiotensin-converting enzyme inhibitors; BMI: body mass index; BP: blood pressure; BUN: blood urea nitrogen; HDL: high density lipoprotein; LDL: low density lipoprotein; N: count; sd: standard deviation; WC: waist circumference; WHR: waist-to-hip ratio.